Cargando…
Identification and Tumour-Binding Properties of a Peptide with High Affinity to the Disialoganglioside GD2
Neuroectodermal tumours are characterized by aberrant processing of disialogangliosides concomitant with high expression of GD2 or GD3 on cell surfaces. Antibodies targeting GD2 are already in clinical use for therapy of neuroblastoma, a solid tumour of early childhood. Here, we set out to identify...
Autores principales: | Müller, Jan, Reichel, Robin, Vogt, Sebastian, Müller, Stefan P., Sauerwein, Wolfgang, Brandau, Wolfgang, Eggert, Angelika, Schramm, Alexander |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055303/ https://www.ncbi.nlm.nih.gov/pubmed/27716771 http://dx.doi.org/10.1371/journal.pone.0163648 |
Ejemplares similares
-
Cross-presentation of Disialoganglioside GD3 to Natural Killer T Cells
por: Wu, Dianna Y., et al.
Publicado: (2003) -
Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes
por: Erber, Ramona, et al.
Publicado: (2021) -
Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins
Publicado: (1986) -
Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy
por: Nazha, Bassel, et al.
Publicado: (2020) -
Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer
por: Reppel, Loïc, et al.
Publicado: (2022)